Bank of America Securities Remains a Buy on Rocket Pharmaceuticals (RCKT)
Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The ...
Business Insider1d
Rocket Pharmaceuticals: Strategic Advancements and Strong Financial Position Justify Buy Rating
Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...
precisionmedicineonline4d
Rocket Pharma Starts Rolling BLA Submission for Fanconi Anemia Gene Therapy
RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.
Yahoo Finance5d
Genezen Welcomes Industry Experts Dr. Pam Stetkiewicz and Stuart Auerbach to Board of Directors
Genezen is a contract development and manufacturing organization (CDMO) with a decade’s experience at the heart of the rapid growth in the gene and cell therapy market. Genezen is a leader in the ...
Le Lézard6d
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
Inc. ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit ...
Stem cells can tailor their role in gene therapy based on the underlying disease, study suggests
RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...